| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb12a064f514f0876c511fc78fbabcad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-265 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate |
2017-06-16^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-04^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4889c86be3f56d936106826da5d7e247
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea3261383858f99e1ac4c5a992fec877
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56ba6429b43d171ef947827388d2c45b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9387bd86da4a6334cd5cecf49edc080
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5160d00cf2c746591226147fa9f397cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70c69e7edcb53c24d6f159b41b6b77c3 |
| publicationDate |
2021-02-04^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2017285448-B2 |
| titleOfInvention |
Pharmaceutical salts of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
| abstract |
Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(l-methyl-lH- indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed. |
| priorityDate |
2016-06-17^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |